INS and Alzheimer disease: The following study specifically looked at how intranasal insulin (INI) affected CSF indicators of inflammation, immunological function, and vascular function, as well as how these markers were related to clinical markers of AD development. As a result, findings demonstrated that INI therapy altered immune function, inflammation, and vascular integrity markers, supporting activation of other immune response mechanisms, suggesting that insulin may alter the progression of AD [17].